TORONTO, Sept. 1, 2022 Khiron Life Sciences Corp. Announces its new medical product portfolio in Europe. The new products, which are already being promoted to prescribers, pharmacies, and patients, will be exclusively distributed through Khiron’s wholly-owned Pharmadrug Production GmbH and will be available to pharmacies and patients in Germany and the UK in the coming weeks.
The THC-dominant full-spectrum extract KHIRIOX 25/1 combines the medicinal properties and areas of application of the established THC isolate formulations (dronabinol) with the specific advantages of a full spectrum extract. This new product is based on Khiron’s current top selling and effective extract formulation in Latin America.
Khiron will also introduce non-irradiated flower varieties KHIRON Gelato 19/1 and KHIRON Caramel 5/7. These varieties are very popular in California among consumers and patients and are in very high demand in Europe.
Franziska Katterbach, President of Khiron Europe, stated: “With the acquisition of Pharmadrug, Khiron is now able to completely control the value chain in Europe, and we can introduce new products that are in high demand in the European market with potential higher margins. With these new additions to our medical portfolio, Khiron Europe now covers the entire spectrum of chemotypes, therapies and routes of administration in the interest of all our European prescribers and patients. With our new medical products, we offer patients what they want and need. Especially our new flower varieties Gelato and Caramel illustrate that medicine does not have to be bitter.”
About Khiron Life Sciences Corp.
Khiron is a medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, the United Kingdom, Peru, and Brazil and is positioned to commence sales in Mexico. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team
About Pharmadrug Production GmbH
Pharmadrug GmbH has been active worldwide for more than 30 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients, as well as holding a licence to handle narcotics in Germany. Pharmadrug GmbH is EU-GMP (Good Manufacturing Practice) and EU-GDP (Good Distribution Practice) certified, fulfilling the European guidelines for the highest quality standards.
(This information is primarily sourced from Khiron Life Sciences Corp. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).